Cargando…

Von Willebrand Disease: An Overview

Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bharati, K. Pavani, Prashanth, U. Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224412/
https://www.ncbi.nlm.nih.gov/pubmed/22131616
http://dx.doi.org/10.4103/0250-474X.89751
_version_ 1782217377891483648
author Bharati, K. Pavani
Prashanth, U. Ram
author_facet Bharati, K. Pavani
Prashanth, U. Ram
author_sort Bharati, K. Pavani
collection PubMed
description Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers which get arranged to give multimers. Binding with plasma proteins (especially factor VIII) is the main function of von Willebrand factor. The disease is of two forms: Inherited and acquired forms. Inherited forms are of three major types. They are type 1, type 2, and type 3; in which type 2 is sub-divided into 2A, 2B, 2M, 2N. Type 1 is more prevalent than all other types. Mucocutaneous bleeding is mild in type 1 whereas it is mild to moderate in types 2A, 2B, and 2M. Type 2N has similar symptoms of haemophilia. The pathophysiology of each type depends on the qualitative or quantitative defects in von Willebrand factor. The diagnosis is based on von Willebrand factor antigen, von Willebrand factor activity assay, FVIII coagulant activity and some other additional tests. Results should be analyzed within the context of blood group. von Willebrand factor multimer analysis is essential for typing and sub typing the disease. The management of the disease involves replacement therapy, non-replacement therapy and other therapies that include antifibrinolytics and topical agents.
format Online
Article
Text
id pubmed-3224412
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-32244122011-11-30 Von Willebrand Disease: An Overview Bharati, K. Pavani Prashanth, U. Ram Indian J Pharm Sci Review Article Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers which get arranged to give multimers. Binding with plasma proteins (especially factor VIII) is the main function of von Willebrand factor. The disease is of two forms: Inherited and acquired forms. Inherited forms are of three major types. They are type 1, type 2, and type 3; in which type 2 is sub-divided into 2A, 2B, 2M, 2N. Type 1 is more prevalent than all other types. Mucocutaneous bleeding is mild in type 1 whereas it is mild to moderate in types 2A, 2B, and 2M. Type 2N has similar symptoms of haemophilia. The pathophysiology of each type depends on the qualitative or quantitative defects in von Willebrand factor. The diagnosis is based on von Willebrand factor antigen, von Willebrand factor activity assay, FVIII coagulant activity and some other additional tests. Results should be analyzed within the context of blood group. von Willebrand factor multimer analysis is essential for typing and sub typing the disease. The management of the disease involves replacement therapy, non-replacement therapy and other therapies that include antifibrinolytics and topical agents. Medknow Publications & Media Pvt Ltd 2011 /pmc/articles/PMC3224412/ /pubmed/22131616 http://dx.doi.org/10.4103/0250-474X.89751 Text en Copyright: © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Bharati, K. Pavani
Prashanth, U. Ram
Von Willebrand Disease: An Overview
title Von Willebrand Disease: An Overview
title_full Von Willebrand Disease: An Overview
title_fullStr Von Willebrand Disease: An Overview
title_full_unstemmed Von Willebrand Disease: An Overview
title_short Von Willebrand Disease: An Overview
title_sort von willebrand disease: an overview
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224412/
https://www.ncbi.nlm.nih.gov/pubmed/22131616
http://dx.doi.org/10.4103/0250-474X.89751
work_keys_str_mv AT bharatikpavani vonwillebranddiseaseanoverview
AT prashanthuram vonwillebranddiseaseanoverview